Bayer Hlthcare patents expiration
1. Adempas patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6743798 | BAYER HLTHCARE | Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
Jul, 2019
(4 years ago) | |
| US7173037 | BAYER HLTHCARE | Carbamate-substituted pyrazolopyridines |
Dec, 2026
(2 years from now) | |
| US10662188 | BAYER HLTHCARE | Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate |
Feb, 2034
(9 years from now) | |
| US11203593 | BAYER HLTHCARE | Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
Feb, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 08, 2020 |
| New Chemical Entity Exclusivity(NCE) | Oct 08, 2018 |
| Orphan Drug Exclusivity(ODE-53) | Oct 08, 2020 |
Drugs and Companies using RIOCIGUAT ingredient
NCE-1 date: 08 October, 2017
Market Authorisation Date: 08 October, 2013
Treatment: Treatment of adults with pulmonary hypertension (pah), (who group 1), to improve exercise capacity, who functional class and to delay clinical worsening
Dosage: TABLET;ORAL
ADEMPAS family patents
2. Angeliq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6933395 | BAYER HLTHCARE | PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY |
Aug, 2017
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8906890 | BAYER HLTHCARE | Very low-dosed solid oral dosage forms for HRT |
Oct, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Mar 01, 2015 |
Drugs and Companies using DROSPIRENONE; ESTRADIOL ingredient
Market Authorisation Date: 29 February, 2012
Treatment: NA
Dosage: TABLET;ORAL
ANGELIQ family patents
3. Astepro Allergy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8518919 | BAYER HLTHCARE | Compositions comprising azelastine and methods of use thereof |
Nov, 2025
(1 year, 6 months from now) | |
| US9919050 | BAYER HLTHCARE | Compositions comprising azelastine |
Nov, 2025
(1 year, 6 months from now) | |
| US8071073 | BAYER HLTHCARE | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(4 years from now) | |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2021
Treatment: Otc use: allergy symptom reliever; Temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose
Dosage: SPRAY, METERED;NASAL
ASTEPRO ALLERGY family patents
4. Avelox patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5607942 | BAYER HLTHCARE | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Mar, 2014
(10 years ago) | |
| US5849752 | BAYER HLTHCARE | Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification |
Dec, 2016
(7 years ago) | |
| US6610327 | BAYER HLTHCARE | Pharmaceutical moxifloxacin preparation |
Oct, 2019
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-185) | Sep 27, 2019 |
Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 10 December, 1999
Treatment: Method of combating bacteria in a patient
Dosage: TABLET;ORAL
AVELOX family patents
5. Avelox In Sodium Chloride 0.8% In Plastic Container patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5607942 | BAYER HLTHCARE | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Mar, 2014
(10 years ago) | |
| US5849752 | BAYER HLTHCARE | Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification |
Dec, 2016
(7 years ago) | |
| US6548079 | BAYER HLTHCARE | Moxifloxacin formulation containing common salt |
Jul, 2020
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-185) | Sep 27, 2019 |
Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 30 November, 2001
Treatment: Method of combating bacteria in a patient
Dosage: SOLUTION;INTRAVENOUS
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER family patents
6. Beyaz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6441168 | BAYER HLTHCARE | Stable crystalline salts of 5-methyltetrahydrofolic acid |
Jul, 2022
(1 year, 8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE37838 | BAYER HLTHCARE | Composition for contraception |
Jun, 2014
(9 years ago) | |
| USRE37564 | BAYER HLTHCARE | Composition for contraception |
Jun, 2014
(9 years ago) | |
| USRE38253 | BAYER HLTHCARE | Composition for contraception |
Jun, 2014
(9 years ago) | |
| USRE43916 | BAYER HLTHCARE | Composition for contraception |
Jun, 2014
(9 years ago) | |
| US5798338 | BAYER HLTHCARE | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol |
Jul, 2015
(8 years ago) | |
| US6958326 | BAYER HLTHCARE | Cyclodextrin-drospirenone inclusion complexes |
Dec, 2021
(2 years ago) | |
| US7163931 | BAYER HLTHCARE | Compositions of estrogen-cyclodextrin complexes |
Mar, 2022
(2 years ago) | |
| US8617597 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Feb, 2030
(5 years from now) | |
| US11617751 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 24, 2013 |
| New Combination(NC) | Sep 24, 2013 |
Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient
Market Authorisation Date: 24 September, 2010
Treatment: Method of inducing contraception in a female of reproductive age who has not yet reached premenopause; Prevention of pregnancy; Treatment of mood changes and/or anxiety as symptoms of premenstrual dys...
Dosage: TABLET;ORAL
BEYAZ family patents
7. Children's Astepro Allergy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9919050 | BAYER HLTHCARE | Compositions comprising azelastine |
Nov, 2025
(1 year, 6 months from now) | |
| US8518919 | BAYER HLTHCARE | Compositions comprising azelastine and methods of use thereof |
Nov, 2025
(1 year, 6 months from now) | |
| US8071073 | BAYER HLTHCARE | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(4 years from now) | |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2021
Treatment: Otc use: allergy symptom reliever; Temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose
Dosage: SPRAY, METERED;NASAL
CHILDREN'S ASTEPRO ALLERGY family patents
8. Cipro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6136347 | BAYER HLTHCARE | Flavor-masked pharmaceutical compositions |
Jan, 2013
(11 years ago) | |
|
US6136347 (Pediatric) | BAYER HLTHCARE | Flavor-masked pharmaceutical compositions |
Jul, 2013
(10 years ago) | |
| US5695784 | BAYER HLTHCARE | Flavor-masked pharmaceutical compositions |
Dec, 2014
(9 years ago) | |
|
US5695784 (Pediatric) | BAYER HLTHCARE | Flavor-masked pharmaceutical compositions |
Jun, 2015
(8 years ago) | |
Drugs and Companies using CIPROFLOXACIN ingredient
Market Authorisation Date: 26 September, 1997
Treatment: Use of approved formulations to treat all approved disease indications
Dosage: FOR SUSPENSION;ORAL
CIPRO family patents
9. Cipro Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7709022 | BAYER HLTHCARE | Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
Jun, 2021
(2 years ago) | |
| US8187632 | BAYER HLTHCARE | Sustained-release preparations of quinolone antibiotics |
Jun, 2021
(2 years ago) | |
|
US7709022 (Pediatric) | BAYER HLTHCARE | Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
Dec, 2021
(2 years ago) | |
|
US8187632 (Pediatric) | BAYER HLTHCARE | Sustained-release preparations of quinolone antibiotics |
Dec, 2021
(2 years ago) | |
Drugs and Companies using CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 13 December, 2002
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
CIPRO XR family patents
10. Climara Pro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5676968 | BAYER HLTHCARE | Transdermal therapeutic systems with crystallization inhibitors |
Oct, 2014
(9 years ago) | |
Drugs and Companies using ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 21 November, 2003
Treatment: NA
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
CLIMARA PRO family patents
11. Eovist patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5798092 | BAYER HLTHCARE | Derivatized DTPA complexes pharmaceutical agents containing these compounds, their use, and processes for their production |
Aug, 2015
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6039931 | BAYER HLTHCARE | Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production |
Nov, 2021
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-155) | Mar 27, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jul 03, 2013 |
Drugs and Companies using GADOXETATE DISODIUM ingredient
NCE-1 date: 03 July, 2012
Market Authorisation Date: 03 July, 2008
Treatment: Magnetic resonance imaging of the liver
Dosage: SOLUTION;INTRAVENOUS
EOVIST family patents
12. Gadavist patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5980864 | BAYER HLTHCARE | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
Nov, 2021
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-801) | Jul 12, 2022 |
| New Indication(I-688) | Jun 11, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 14, 2016 |
| New Indication(I-731) | Apr 27, 2019 |
Drugs and Companies using GADOBUTROL ingredient
NCE-1 date: 15 March, 2015
Market Authorisation Date: 18 December, 2013
Treatment: Contrast agent for magnetic resonance imaging
Dosage: SOLUTION;INTRAVENOUS
GADAVIST family patents
13. Kerendia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8436180 | BAYER HLTHCARE | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
Apr, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 09, 2026 |
| M(M-279) | Sep 01, 2025 |
Drugs and Companies using FINERENONE ingredient
NCE-1 date: 09 July, 2025
Market Authorisation Date: 09 July, 2021
Treatment: NA
Dosage: TABLET;ORAL
KERENDIA family patents
14. Kyleena patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7252839 | BAYER HLTHCARE | Delivery system and a manufacturing process of a delivery system |
Nov, 2023
(5 months ago) | |
| US11628088 | BAYER HLTHCARE | Ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection |
Feb, 2027
(2 years from now) | |
| US9615965 | BAYER HLTHCARE | Inserter |
Sep, 2029
(5 years from now) | |
| US10561524 | BAYER HLTHCARE | Inserter |
Sep, 2029
(5 years from now) | |
| US10987244 | BAYER HLTHCARE | Inserter |
Apr, 2031
(6 years from now) | |
| US9668912 | BAYER HLTHCARE | Inserter |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 16, 2019 |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 16 September, 2016
Treatment: A method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to rele...
Dosage: INTRAUTERINE DEVICE;INTRAUTERINE
KYLEENA family patents
15. Levitra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7696206 | BAYER HLTHCARE | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
Oct, 2018
(5 years ago) | |
| US6362178 | BAYER HLTHCARE | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
Oct, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8841446 | BAYER HLTHCARE | Medicaments containing vardenafil hydrochloride trihydrate |
Jul, 2023
(9 months ago) | |
| US8273876 | BAYER HLTHCARE | Medicaments containing vardenafil hydrochloride trihydrate |
Jul, 2027
(3 years from now) | |
Drugs and Companies using VARDENAFIL HYDROCHLORIDE ingredient
Market Authorisation Date: 19 August, 2003
Treatment: Treatment of erectile dysfunction by administering a film-coated tablet; Erectile dysfunction
Dosage: TABLET;ORAL
LEVITRA family patents
16. Menostar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6692763 | BAYER HLTHCARE | Methods for treating postmenopausal women using ultra-low doses of estrogen |
Nov, 2017
(6 years ago) | |
| US5891868 | BAYER HLTHCARE | Methods for treating postmenopausal women using ultra-low doses of estrogen |
Nov, 2017
(6 years ago) | |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 08 June, 2004
Treatment: Prevention of postmenopausal osteoporosis
Dosage: SYSTEM;TRANSDERMAL
MENOSTAR family patents
17. Mirena patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5785053 | BAYER HLTHCARE | Inserter for the positioning of an intrauterine device |
Dec, 2015
(8 years ago) | |
| US9615965 | BAYER HLTHCARE | Inserter |
Sep, 2029
(5 years from now) | |
| US10561524 | BAYER HLTHCARE | Inserter |
Sep, 2029
(5 years from now) | |
| US10987244 | BAYER HLTHCARE | Inserter |
Apr, 2031
(6 years from now) | |
| US9668912 | BAYER HLTHCARE | Inserter |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-181) | Aug 20, 2023 |
| New Indication(I-610) | Oct 01, 2012 |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 06 December, 2000
Treatment: A method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to rele...
Dosage: INTRAUTERINE DEVICE;INTRAUTERINE
MIRENA family patents
18. Natazia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6133251 | BAYER HLTHCARE | Combination compound for contraception based on natural estrogen |
Oct, 2016
(7 years ago) | |
| US6884793 | BAYER HLTHCARE | Combination preparation for contraception based on natural estrogens |
Oct, 2016
(7 years ago) | |
| US8071577 | BAYER HLTHCARE | Multi-phase contraceptive preparation based on a natural estrogen |
May, 2026
(2 years from now) | |
| US8153616 | BAYER HLTHCARE | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-648) | Mar 14, 2015 |
| New Product(NP) | May 06, 2013 |
Drugs and Companies using DIENOGEST; ESTRADIOL VALERATE ingredient
Market Authorisation Date: 06 May, 2010
Treatment: Prevention of pregnancy; Treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception
Dosage: TABLET;ORAL
NATAZIA family patents
19. Nexavar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7235576 | BAYER HLTHCARE | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(4 years ago) | |
| US7351834 | BAYER HLTHCARE | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(4 years ago) | |
| US8877933 | BAYER HLTHCARE | Thermodynamically stable form of a tosylate salt |
Dec, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8841330 | BAYER HLTHCARE | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(4 years ago) | |
| US8124630 | BAYER HLTHCARE | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(4 years ago) | |
| US7897623 | BAYER HLTHCARE | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
Jan, 2020
(4 years ago) | |
| US8618141 | BAYER HLTHCARE | Aryl ureas with angiogenesis inhibiting activity |
Feb, 2023
(1 year, 2 months ago) | |
| US9737488 | BAYER HLTHCARE | Pharmaceutical composition for the treatment of cancer |
Sep, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-677) | Nov 22, 2016 |
| Orphan Drug Exclusivity(ODE-56) | Nov 22, 2020 |
| Orphan Drug Exclusivity(ODE) | Dec 20, 2012 |
Drugs and Companies using SORAFENIB TOSYLATE ingredient
Market Authorisation Date: 20 December, 2005
Treatment: Treatment of unresectable hepatocellular carcinoma; Treatment of carcinoma of the thyroid; Treatment of advanced renal cell carcinoma; Treatment of unresectable hepatocellular carcinoma, advanced rena...
Dosage: TABLET;ORAL
NEXAVAR family patents
20. Safyral patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6441168 | BAYER HLTHCARE | Stable crystalline salts of 5-methyltetrahydrofolic acid |
Apr, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5798338 | BAYER HLTHCARE | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol |
Jul, 2015
(8 years ago) | |
| US6958326 | BAYER HLTHCARE | Cyclodextrin-drospirenone inclusion complexes |
Dec, 2021
(2 years ago) | |
| US7163931 | BAYER HLTHCARE | Compositions of estrogen-cyclodextrin complexes |
Mar, 2022
(2 years ago) | |
| US8617597 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Feb, 2030
(5 years from now) | |
| US11617751 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 16, 2013 |
Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient
Market Authorisation Date: 16 December, 2010
Treatment: Prevention of pregnancy; Raise folate levels in women who choose to use an oral contraceptive as their method of contraception for the purpose of reducing the risk of a neural tube defect in a pregnan...
Dosage: TABLET;ORAL
SAFYRAL family patents
21. Skyla patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5785053 | BAYER HLTHCARE | Inserter for the positioning of an intrauterine device |
Dec, 2015
(8 years ago) | |
| US7252839 | BAYER HLTHCARE | Delivery system and a manufacturing process of a delivery system |
Nov, 2023
(5 months ago) | |
| US11628088 | BAYER HLTHCARE | Ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection |
Feb, 2027
(2 years from now) | |
| US9615965 | BAYER HLTHCARE | Inserter |
Sep, 2029
(5 years from now) | |
| US10561524 | BAYER HLTHCARE | Inserter |
Sep, 2029
(5 years from now) | |
| US9668912 | BAYER HLTHCARE | Inserter |
Apr, 2031
(6 years from now) | |
| US10987244 | BAYER HLTHCARE | Inserter |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 09, 2016 |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 09 January, 2013
Treatment: A method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to rele...
Dosage: INTRAUTERINE DEVICE;INTRAUTERINE
SKYLA family patents
22. Staxyn patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7696206 | BAYER HLTHCARE | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
Oct, 2018
(5 years ago) | |
| US6362178 | BAYER HLTHCARE | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
Oct, 2018
(5 years ago) | |
| US8613950 | BAYER HLTHCARE | Pharmaceutical forms with improved pharmacokinetic properties |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jun 17, 2013 |
Drugs and Companies using VARDENAFIL HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2010
Treatment: Treatment of erectile dysfunction
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
STAXYN family patents
23. Stivarga patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7351834 | BAYER HLTHCARE | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jun, 2022
(1 year, 9 months ago) | |
| US8637553 | BAYER HLTHCARE | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
Feb, 2031
(6 years from now) | |
| US9957232 | BAYER HLTHCARE | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate |
Jul, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8680124 | BAYER HLTHCARE | Treatment of cancers with acquired resistance to kit inhibitors |
Jun, 2030
(6 years from now) | |
| US9458107 | BAYER HLTHCARE | Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-139) | Apr 27, 2024 |
| New Indication(I-744) | Apr 27, 2020 |
| Orphan Drug Exclusivity(ODE-44) | Feb 25, 2020 |
| Orphan Drug Exclusivity(ODE) | Feb 25, 2020 |
| New Chemical Entity Exclusivity(NCE) | Sep 27, 2017 |
| New Indication(I-667) | Feb 25, 2016 |
Drugs and Companies using REGORAFENIB ingredient
NCE-1 date: 27 September, 2016
Market Authorisation Date: 27 September, 2012
Treatment: Treatment of patients with gastrointestinal stromal tumor (gist), including but not limited to patients previously treated with imatinib and patients with gist having resistance to a kit tyrosine kina...
Dosage: TABLET;ORAL
STIVARGA family patents
24. Vitrakvi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9127013 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US8513263 | BAYER HLTHCARE | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
Dec, 2029
(5 years from now) | |
| US10172861 | BAYER HLTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(11 years from now) | |
| US10799505 | BAYER HLTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Aug, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9676783 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US8865698 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US10005783 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US10047097 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US10774085 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US9447104 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US10285993 | BAYER HLTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(11 years from now) | |
| US9782414 | BAYER HLTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(11 years from now) | |
| US10813936 | BAYER HLTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-215) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-220) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-221) | Nov 26, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 26, 2023 |
Drugs and Companies using LAROTRECTINIB SULFATE ingredient
NCE-1 date: 26 November, 2022
Market Authorisation Date: 26 November, 2018
Treatment: Method of treating cancerous solid tumors; Method of treating neuroblastoma, glioma, thyroid, and breast cancer solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhi...
Dosage: CAPSULE;ORAL
VITRAKVI family patents
25. Xofigo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6635234 | BAYER HLTHCARE | Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning |
Nov, 2022
(1 year, 5 months ago) | |
| US8791127 | BAYER HLTHCARE | Mucosal bioadhesive slow release carrier for delivering active principles |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2018 |
Drugs and Companies using RADIUM RA-223 DICHLORIDE ingredient
NCE-1 date: 15 May, 2017
Market Authorisation Date: 15 May, 2013
Treatment: Therapeutic treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease
Dosage: SOLUTION;INTRAVENOUS
XOFIGO family patents
26. Yasmin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6933395 | BAYER HLTHCARE | PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY |
Aug, 2017
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5569652 | BAYER HLTHCARE | Dihydrospirorenone as an antiandrogen |
Oct, 2013
(10 years ago) | |
| US6787531 | BAYER HLTHCARE | Pharmaceutical composition for use as a contraceptive |
Aug, 2020
(3 years ago) | |
Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL ingredient
Market Authorisation Date: 11 May, 2001
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL-28
YASMIN family patents
27. Yaz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5569652 | BAYER HLTHCARE | Dihydrospirorenone as an antiandrogen |
Oct, 2013
(10 years ago) | |
| USRE38253 | BAYER HLTHCARE | Composition for contraception |
Jun, 2014
(9 years ago) | |
| USRE37838 | BAYER HLTHCARE | Composition for contraception |
Jun, 2014
(9 years ago) | |
| USRE37564 | BAYER HLTHCARE | Composition for contraception |
Jun, 2014
(9 years ago) | |
| USRE43916 | BAYER HLTHCARE | Composition for contraception |
Jun, 2014
(9 years ago) | |
| US5798338 | BAYER HLTHCARE | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol |
Jul, 2015
(8 years ago) | |
| US6933395 | BAYER HLTHCARE | PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY |
Aug, 2017
(6 years ago) | |
| US6987101 | BAYER HLTHCARE | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
Dec, 2017
(6 years ago) | |
| US6787531 | BAYER HLTHCARE | Pharmaceutical composition for use as a contraceptive |
Aug, 2020
(3 years ago) | |
| US7163931 | BAYER HLTHCARE | Compositions of estrogen-cyclodextrin complexes |
Dec, 2021
(2 years ago) | |
| US6958326 | BAYER HLTHCARE | Cyclodextrin-drospirenone inclusion complexes |
Dec, 2021
(2 years ago) | |
Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL ingredient
Market Authorisation Date: 16 March, 2006
Treatment: Prevention of pregnancy; Method of inducing contraception in a female of reproductive age who has not yet reached premenopause; Treatment of symptoms of premenstrual dysphoric disorder
Dosage: TABLET;ORAL
YAZ family patents